The dosage of Kangfuxi produced in Chengdu is 0.2 ml, and the price is 5000/ piece, while the Lanizumab produced in the United States is 5700/ piece.
Compaxip is a recombinant fusion protein (immunoglobulin-like region 2 in human vascular endothelial growth factor VEGF receptor 1 and globulin-like regions 3 and 4 fused with human immunoglobulin Fc fragment) produced by China hamster ovary (CHO) cell expression system.
Extended data:
On 20 1 1 year, the World Health Organization considered Compaxip in 5 1 International Naming Conference, and its English name was "Conbercept". It is an anti-vascular endothelial growth factor fusion protein. The patent holder is Chengdu Kanghong Biotechnology Co., Ltd., which can inhibit pathological angiogenesis.
The international non-patented name of FP3 protein (a fusion protein that inhibits angiogenesis) is the active protein of KH902 and KH903, a new drug of Chengdu Kanghong Pharmaceutical Co., Ltd., which has been approved for marketing, and the English common name is "Conbercept", and the State Pharmacopoeia Committee has been notified.
In 20 12, the world health organization listed "Conbercept" in the 67th batch of international non-proper names recommendation list.
Baidu Encyclopedia-Compaq Xipu
People's Network-Reduce the burden on patients, and macular degeneration drugs enter medical insurance.